Navigation Links
Clarient Reports Second Quarter Revenue Up 40 Percent
Date:8/4/2009

ce Chairman and Chief Executive Officer. "What has changed is the strength of our balance sheet and reaching critical mass in terms of revenues - finally putting us in a position to realize the operating leverage and profits that are possible under this business model. In the second quarter, profits were constrained by investments in much needed infrastructure initiatives, so it is very gratifying for our entire team that we were able to balance these investments and still post our first net income from continuing operations."

The Company's operating income for the second quarter of 2009 was $771 thousand compared with an operating loss of $1.7 million for the same period of 2008. For the six months ended June 30, 2009, operating income was $2.3 million versus an operating loss of $1.9 million for the six months ended June 30, 2008.

Clarient's net income for the quarter was $29 thousand. However, the net amount applicable to common shareholders was a loss of $4.3 million, or $0.06 per share. This was due to a $4.3 million non-cash deemed dividend arising from a "beneficial conversion feature" in the second tranche of the Oak Purchase Agreement. This "in-the-money non-detachable" conversion feature of the issued 1.4 million Preferred Shares gave Oak Investment Partners the opportunity to convert their Preferred Shares into 5.6 million common shares at a $1.90 per share. This was $0.75 below the market price of $2.65 at May 14, 2009, the date of the second Oak closing. In the second quarter of 2008, the Company reported a loss of $4.3 million and a $0.06 loss per share.

For the first six months of 2009, the net loss was $127 thousand, or $0.02 loss per share, compared with a net loss of $5.2 million, or $0.07 loss per share. Net loss applicable to common stockholders for this year's six-month period, including the non-cash deemed dividend mentioned above and a $1.5 million gain on discontinued operations fro
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Clarient to Present at the UBS 2007 Global Life Sciences Conference
2. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
3. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
4. Clarient Generates 52% Revenue Increase in Third Quarter 2007
5. Clarient Named to Deloittes 2007 Orange County Technology Fast 50 for Third Consecutive Year
6. Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference
7. Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
8. Clarient Reports First Quarter 2008
9. Clarient Partners With Joint Venture Hospital Laboratories to Offer Pathologists Wide Array of Cancer Assays
10. Clarient Renews and Expands Mezzanine Credit Facility With Safeguard
11. Clarient Reschedules Fourth Quarter and Year-End 2008 Financial Results Release To Wednesday, March 11th; Conference Call and Webcast Rescheduled For 5:00 PM EDT That Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... date of its industry-defining contract lifecycle management solution, as well as announced the ... to increase the speed and ease of contract management tasks as well as ...
(Date:8/3/2015)... Alachua, FL (PRWEB) , ... August 03, 2015 , ... ... peripheral nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, ... , A live webcast and subsequent archived replay of the Company’s presentation may be ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
(Date:8/3/2015)... ... August 03, 2015 , ... From 2006-2017 the number of ... to market research compiled for the National Association of Dental Laboratories ( NADL ... Bureau of Labor Statistics. As the number of dental laboratories decreases, dentists will ...
(Date:8/3/2015)... Ramon, CA (PRWEB) , ... August 03, 2015 ... ... leading global insurance brokerage firm, announced today that Joe Williams has joined its ... development, sales, and delivering HUB's differentiated service model to his clients. Mr. Williams ...
Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... CITY)Research into how carbohydrates are converted into energy has ... treatment of a perplexing and potentially fatal neuromuscular disorder ... this study, the cause of this neuromuscular disorder was ... members who have the disorder, a team led by ...
... , THURSDAY, May 24 (HealthDay News) -- While fewer people ... of strokes has remained about the same, health officials report. ... nation,s so-called "stroke belt." According to the report on ... strokes dipped slightly from 2.7 percent to 2.6 percent during ...
... a new, higher-yield, two-step, less costly process that may ... material essential for making the mainstay drug for malaria. ... more than 1 million. The report on the process, ... implemented by drug companies, appears in ACS, journal ...
... most comprehensive analyses to date of the cost of robotic-assisted, ... this now-dominant surgical approach is significantly more costly than standard ... outcomes. The results of the study are available online and ... Urology . In one of the first studies ...
... The British Association for Psychopharmacology (BAP) has released ... abuse and addiction in the Journal of Psychopharmacology ... carefully researched the new, comprehensive guidelines, offering practitioners a ... their clinical decisions. The new BAP guidelines target ...
... May 22 (HealthDay News) -- New research suggests that ... anticholinergics -- such as ipratropium [Atrovent] -- could be ... irregular heartbeat. However, the increased risk was ... this finding raises concern because of the recent interest ...
Cached Medicine News:Health News:Pivotal role for proteins -- from helping turn carbs into energy to causing devastating disease 2Health News:Strokes More Common in Southern States: CDC 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 3Health News:British experts update addiction treatment guidelines 2Health News:Asthma Meds May Be Linked to Irregular Heartbeat 2
(Date:8/3/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 3, ... therapeutics for the treatment of cancer, today announced ... team. Debanjan Ray , who ... and alliance management, has been promoted to senior ... to joining CytomX, Mr. Ray held positions as ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
(Date:8/3/2015)... (PK:ECIA), a medical device company owning patented surgical technology ... surgery, today announced financial results for its fiscal 2016 ... The Company posted quarterly net revenue of $2.454 million ... $(0.02) per share. These results compare to net revenue ... thousand, or $(0.02) per share, in the year-ago quarter. ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... 15 Watermark Medical , Inc., a privately-held, ... market, has expanded the market reach of its Web-enabled ... three leading sleep solution providers in the U.S. and ... national provider of comprehensive sleep apnea services; Sleep ...
... Vista Partners announced today that it has updated ... Principal Analyst at Vista Partners stated, "Raptor is potentially ... a balanced pipeline of clinical and preclinical programs.  The ... programs and one Phase 3 trial with some indications ...
Cached Medicine Technology:Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 2Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 3Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 4
... low osmolar, nonionic, contrast media agent ... inert when injected intra-arterially. Each milliliter ... ioversol, 3.6 mg of tromethamine as ... edetate calcium disodium as a stabilizer. ...
... OMNIPAQUE is an X-ray ... adults and children for: angiography, ... and computed tomography of the ... Arthrography, endoscopic retrograde cholangio (pancreato) ...
... IMAGOPAQUE is a non-ionic monomeric contrast medium ... adults and children. After a decade of ... million examinations, IMAGOPAQUE has proven to be ... in hundreds of radiology departments.Results from large ...
... The only MR contrast agent FDA-approved for ... a gadolinium based, IV contrast media for ... liver. OptiMARK has convenient packaging options ... packaged for efficient, problem-free delivery. You can ...
Medicine Products: